Clinical note. Phase II study of 1-aminocyclopentanecarboxylic acid (NSC-1026) in patients with cancer.
D000596:Amino Acids / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003110:Colonic Neoplasms / Q000188:drug therapy; D003517:Cyclopentanes / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D005069:Evaluation Studies as Topic; D001068:Feeding and Eating Disorders / Q000139:chemically induced; D006258:Head and Neck Neoplasms / Q000188:drug therapy; D006801:Humans; D007890:Leiomyosarcoma / Q000188:drug therapy; D008297:Male; D009369:Neoplasms / Q000188:drug therapy*; D012004:Rectal Neoplasms / Q000188:drug therapy; D012509:Sarcoma / Q000188:drug therapy; D013736:Testicular Neoplasms / Q000188:drug therapy; D014633:Valine / Q000037:antagonists & inhibitors; D014839:Vomiting / Q000139:chemically induced
D000596:Amino Acids; D003517:Cyclopentanes; D014633:Valine